Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) announced publication of the analytical validation of the FirstGene Multiple Prenatal Screen in Clinical Chemistry on February 19, 2026. Using nearly 500 samples, the study reported each test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity.
The assay evaluates fetal aneuploidy, RhD compatibility, and recessive condition status for the pregnant person and fetus across 19 prevalent severe conditions. The test uses fetal-fraction amplification and a trajectory analysis algorithm to improve genotype resolution and reproducibility, which the company says supports broader commercialization efforts.
Myriad Genetics (NASDAQ: MYGN) will release its fourth quarter and full year 2025 financial results and hold an earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The earnings release will be issued after market close the same day.
Management will provide a financial overview and business update; a live webcast and archived replay will be available at the company's Investor Relations website. Company executives will also appear at three investor healthcare conferences in March 2026.
Myriad Genetics (NASDAQ: MYGN) plans a limited clinical launch of Precise MRD in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later in 2026, with potential further expansion in 2027.
Key study data show ultrasensitive ctDNA detection down to 1 part-per-million, 93% baseline sensitivity in MONITOR-Breast, and 100% baseline detection plus 100% one-month post-surgery sensitivity for recurrence prediction in MONSTAR-SCREEN-3; one-month postoperative ctDNA positivity was linked to shorter disease-free survival (median follow-up ~6 months, p<0.001).
Myriad Genetics (NASDAQ: MYGN) released select unaudited preliminary results for Q4 and full year 2025 and introduced full‑year 2026 guidance on Jan 12, 2026.
Preliminary revenue: Q4 2025 $207M–$209M; full year 2025 $822M–$824M. 2026 guidance: Revenue $860M–$880M, Adjusted Gross Margin 68%–69%, and Adjusted EBITDA $37M–$49M. The company will publish final audited results in February 2026 and host a webcast on Jan 14, 2026 at 5:15 pm PT.
Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) announced it will present 8 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Dec. 10–11, 2025, covering MRD, germline testing, somatic profiling, and polygenic risk.
Key highlights include new data on the Precise Molecular Residual Disease (MRD) Test—a tumor-informed, WGS-based assay with custom selection of up to 1,000 variants and reported ultra-sensitivity at low tumor fractions (RUO)—and updates to the MyRisk Hereditary Cancer Test expanded to 63 genes. Myriad will sponsor a Product Theater session on Dec. 10 (2:30–3:30 p.m. CST) and host a booth (#1414) during exhibition hours.
Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.
The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.
The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.
Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.
The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.
Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.
Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.
Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.